DBV Technologies | DBVT - Fremdkapital

Aktienkurs
18.46
Täglich Wechseln
-0.29 -1.55%
Monatlich
-12.10%
Jährlich
92.29%
Q2 Prognose
19.19




Fremdkapital Veränderung Datum
Acadia Pharmaceuticals USD 0 0 2025-03
Alnylam Pharmaceuticals USD 2.48B 931K 2026-03
BioCryst Pharmaceuticals USD 395.2M 33.48M 2026-03
BioMarin Pharmaceutical USD 1.43B 833.11M 2026-03
DBV Technologies USD 0 0 2025-03
Esperion Therapeutics USD 457.65M 9.5M 2025-12
Galectin Therapeutics USD 93.42M 9.08M 2024-06
Halozyme Therapeutics USD 1.94B 206.73M 2026-03
Incyte USD 29.41M 785K 2026-03
Insmed USD 542.22M 1.25M 2026-03
Ionis Pharmaceuticals USD 1.91B 9M 2026-03
Neurocrine Biosciences USD 169.5M 500K 2023-03
PTC Therapeutics USD 286.94M 1.74B 2026-03
Sarepta Therapeutics USD 838.16M 9.19M 2026-03
Ultragenyx Pharmaceutical USD 1.13B 19M 2026-03
United Therapeutics USD 100M 100M 2024-06